Michelle Glass
{{Short description|New Zealand pharmacology academic}}
{{Use dmy dates|date=August 2018}}
{{Use New Zealand English|date=August 2018}}
{{Infobox scientist
| name = Michelle Glass
| native_name =
| native_name_lang =
| image =
| image_size =
| alt =
| caption =
| birth_date =
| birth_place =
| death_date =
| death_place =
| resting_place =
| resting_place_coordinates =
| other_names =
| citizenship =
| nationality =
| fields = Pharmacology of cannabinoid receptors
| workplaces = University of Auckland, University of Otago
| patrons =
| alma_mater = University of Auckland
| thesis1_title = Receptor alterations in human neuro-degenerative diseases
| thesis1_url = https://catalogue.library.auckland.ac.nz/primo-explore/fulldisplay?docid=uoa_alma21172673150002091&context=L&vid=NEWUI&search_scope=Combined_Local&tab=combined&lang=en_US
| thesis1_year = 1994
| doctoral_advisor =
| academic_advisors =
| doctoral_students =
| notable_students =
| known_for =
| author_abbrev_bot =
| author_abbrev_zoo =
| influences =
| influenced =
| awards =
| signature =
| signature_alt =
| website =
| footnotes =
| spouse =
| children =
}}
Michelle Glass {{Post-nominals|country=NZL|FRSNZ}} is a New Zealand pharmacology academic. She is currently a full professor and Head of the Department of Pharmacology & Toxicology at the University of Otago.{{Cite web|url=https://www.otago.ac.nz/phal/people/profile/index.html?id=2996|title = Staff profile at the Department of Pharmacology & Toxicology}}
Career
Since a 1994 PhD titled 'Receptor alterations in human neuro-degenerative diseases' at the University of Auckland, she has worked at both the University of Auckland and the University of Otago, rising to full professor.{{cite web|url=https://unidirectory.auckland.ac.nz/profile/m-glass|title=Professor Michelle Glass - The University of Auckland|website=unidirectory.auckland.ac.nz}}
Glass's primary work has been on cannabinoids and they have received multiple grants for the work{{cite web|url=https://www.stuff.co.nz/auckland/local-news/5738153/Researchers-split-53m-fund|title=Researchers split $53m fund|website=Stuff|date=5 October 2011}}{{cite web|url=https://www.radionz.co.nz/news/national/309081/$157,000-to-study-cannabinoids'-effect-on-brain-cancer|title=$157,000 to study cannabinoids' effect on brain cancer|date=20 July 2016|publisher=}} and considerable press attention.{{cite web|url=https://www.odt.co.nz/news/dunedin/demystifying-synthetic-cannabis|title=Demystifying synthetic cannabis|date=10 August 2018|publisher=}}{{cite news|url=https://www.newshub.co.nz/home/health/2017/09/killer-synthetic-drug-was-never-tested-on-humans.html|archive-url=https://web.archive.org/web/20170920013316/http://www.newshub.co.nz/home/health/2017/09/killer-synthetic-drug-was-never-tested-on-humans.html|url-status=dead|archive-date=20 September 2017|title=Killer synthetic drug was never tested on humans|newspaper=Newshub |date=16 September 2017|publisher=}}{{cite news|url=https://www.tvnz.co.nz/one-news/new-zealand/why-synthetic-cannabis-killing-kiwis-more-than-anyone-else-in-world|title=Why is synthetic cannabis killing Kiwis more than anyone else in the world?|publisher=|newspaper=TVNZ}}{{cite web|url=https://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=11896693|title=Minister and drug expert: 'Tell us what's in killer synthetic cannabis'|first=Simon Collins Education reporter, NZ Herald|last=simon.collins@nzherald.co.nz|date=29 July 2017|publisher=|via=www.nzherald.co.nz}} She has also been involved in a documentary 'Mum, Cannabis and Me'{{cite news|url=https://www.newshub.co.nz/home/entertainment/2017/09/med-student-s-heartfelt-medicinal-marijuana-documentary-mum-cannabis-and-me-premieres.html|archive-url=https://web.archive.org/web/20170930053341/http://www.newshub.co.nz/home/entertainment/2017/09/med-student-s-heartfelt-medicinal-marijuana-documentary-mum-cannabis-and-me-premieres.html|url-status=dead|archive-date=30 September 2017|title=Med student's heartfelt medicinal marijuana documentary Mum, Cannabis and Me premieres|newspaper=Newshub |date=8 September 2017|publisher=}}{{cite web|url=http://www.stuff.co.nz/national/health/96559017/mum-cannabis-and-me-documentary-premier-challenges-medicinal-cannabis-use|title=Mum, Cannabis and Me documentary premier challenges medicinal cannabis use|website=Stuff|date=7 September 2017}}{{cite web|url=http://gisborneherald.co.nz/localnews/3064840-135/mum-cannabis-and-me-to-screen|title=Mum, cannabis and me to screen tomorrow|publisher=}}{{cite web|url=http://www.scoop.co.nz/stories/GE1708/S00121/educational-docco-world-premiere-mum-cannabis-and-me.htm|title=Educational Docco World Premiere - 'Mum, Cannabis, And Me' - Scoop News|website=www.scoop.co.nz}}
More recently, Prof Glass has applied her expertise in G protein-coupled receptors to the forest pathogen, kauri dieback. In 2018, she received a grant from the Marsden Fund entitled "Applying human drug discovery approaches to kauri dieback"{{Cite web|url=https://royalsociety.org.nz/what-we-do/funds-and-opportunities/marsden/awarded-grants/marsden-fund-highlights/2018-marsden-fund-highlights/saving-kauri-with-a-human-drug-discovery-approach/|title=Royal Society Te Apārangi - Saving kauri with a human drug discovery approach|website=royalsociety.org.nz|access-date=2019-01-18}}
In 2024 Glass was elected as a Fellow of the Royal Society Te Apārangi.{{Cite web |last=Otago |first=University of |date=2024-04-04 |title=Hidden worlds of Otago’s new Royal Society Fellows |url=https://www.otago.ac.nz/news/newsroom/hidden-worlds-of-otagos-new-royal-society-fellows |access-date=2024-04-04 |website=www.otago.ac.nz |language=en}}
Selected works
- Glass, M., R. L. M. Faull, and M. Dragunow. "Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain." Neuroscience 77, no. 2 (1997): 299–318.
- Glass, Michelle, and Christian C. Felder. "Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor." Journal of Neuroscience 17, no. 14 (1997): 5327–5333.
- Buckley, Nancy E., Kathleen L. McCoy, Éva Mezey, Tom Bonner, Anne Zimmer, Christian C. Felder, Michelle Glass, and Andreas Zimmer. "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor." European Journal of Pharmacology 396, no. 2-3 (2000): 141–149.
- Glass, M., M. Dragunow, and R. L. M. Faull. "The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease." Neuroscience 97, no. 3 (2000): 505–519.
- Felder, Christian C., and Michelle Glass. "Cannabinoid receptors and their endogenous agonists." Annual Review of Pharmacology and toxicology 38, no. 1 (1998): 179–200.
- Kearn, Christopher S., Katherine Blake-Palmer, Emma Daniel, Ken Mackie, and Michelle Glass. "Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor crosstalk?." Molecular Pharmacology (2005).
- Robson, Hunter, Rhiannon Braund, Michelle Glass, Janelle Ashton, Michael Tatley. "Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre." Clinical Toxicology (2020).
References
{{Reflist}}
External links
- {{ResearchGate | id= Michelle_Glass}}
{{Authority control}}
{{DEFAULTSORT:Glass, Michelle}}
Category:New Zealand pharmacologists
Category:New Zealand women academics
Category:Recipients of Marsden grants
Category:Year of birth missing (living people)
Category:New Zealand women writers
{{NewZealand-academic-bio-stub}}